Refining method of favipiravir

A favipiravir and refining method technology, applied in new refining fields, can solve the problems of multiple impurities, low yield of body pure recrystallization, difficult to prepare high-purity favipiravir with high yield, and achieve simple Operation, the effect of excellent crystallinity
CN112645889APending Publication Date: 2021-04-13HANGZHOU HUANGSEN BIOLOGICAL TECH CO LTD
5 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HANGZHOU HUANGSEN BIOLOGICAL TECH CO LTD
Publication Date
2021-04-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a refining method of favipiravir. The method specifically comprises the following steps: 6-fluoro-3-hydroxy-2-cyanopyrazine reacts with hydrogen peroxide under an alkaline condition to obtain 6-fluoro-3-hydroxy-2-pyrazinamide; the 6-fluoro-3-hydroxy-2-pyrazinamide is prepared into an organic alkali salt in an anhydrous organic solvent, and then the pH value in water is adjusted to prepare high-purity 6-fluoro-3-hydroxy-2-pyrazinamide; and 6-fluoro-3-hydroxy-2-pyrazinamide and organic alkali are salified in an organic solvent, the salt has excellent crystallinity, high-purity favipiravir can be prepared with high yield through simple operation, the yield can reach 90% or above, and the HPLC purity reaches 99.9% or above.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a novel refining method of Favipiravir. Background technique

[0002] Favipiravir (favipiravir, T-705, trade name Avigan, 1), the chemical name is 6-fluoro-3-hydroxy-2-pyrazine carboxamide, is a target RNA-dependent drug developed by Japan Toyama Chemical Pharmaceutical Co., Ltd. A new broad-spectrum antiviral drug based on RNA polymerase (RdRp), which was approved for marketing in Japan in March 2014, for the treatment of new and recurrent influenza. At present, phase III clinical research on anti-influenza A has been completed in the United States. Favipiravir has a good therapeutic effect on patients infected with Ebola virus, and phase II clinical research on anti-Ebola virus is being conducted in the United States. The mechanism of action of favipiravir is mainly that after entering the body, under the action of a series of cellular phosphokinases, it generates the form of its nucleoside analog triphosphate, thereby inter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More